Markedsdata leveret af TwelveData og Morningstar
HYTN Innovations Inc. is a Canadian pharmaceutical and healthcare company specializing in products containing psychoactive and psychotropic compounds, with a primary focus on cannabis-derived cannabinoids. The company formulates, manufactures, markets, and sells premium cannabis goods, including edible cannabis, cannabis-infused beverages, nano-shot formats, and cannabis flower, serving both medical and adult-use markets. HYTN Innovations Inc. operates as a Good Manufacturing Practice (GMP) processor and active pharmaceutical ingredient (API) fabricator, supplying pharmaceutical-grade cannabinoid medicines and ingredients to regulated markets such as Canada, Australia, the United Kingdom, and Germany. It also maintains capabilities for GMP psilocybin mushroom manufacturing and other restricted input materials for domestic and international partners. Headquartered in Kelowna, British Columbia, the company plays a niche role at the intersection of life sciences, pharmaceuticals, and cannabis consumer packaged goods by combining high regulatory standards with scalable manufacturing for global, federally regulated channels.